Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
Guidi L, Pugliese D, Panici Tonucci T, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A.
Guidi L, et al. Among authors: papa a.
United European Gastroenterol J. 2019 Nov;7(9):1189-1197. doi: 10.1177/2050640619873784. Epub 2019 Sep 3.
United European Gastroenterol J. 2019.
PMID: 31700632
Free PMC article.